Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Vary

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|April 1, 1984
Mechanism by which hydralazine increases propranolol bioavailabilityD W Schneck, J E Vary
Clinical Pharmacology and Therapeutics|June 1, 1980
Effect of dose and uremia on plasma and urine profiles of propranolol metabolitesD W Schneck, J F Pritchard, T P Gibson, et al.
Clinical Pharmacology and Therapeutics|May 1, 1990
Novel multivalent effects of pyrazinoylguanidine in patients with azotemiaK H Beyer, R T Gelarden, J E Vary, et al.
Clinical Pharmacology and Therapeutics|December 1, 1978
Plasma levels of free and acid-labile hydralazine: effects of multiple dosing and of procainamideD W Schneck, J S Sprouse, K Miller, et al.
Journal of Clinical Pharmacology|June 1, 1993
Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiencyK H Beyer, T D Ward, J E Vary, et al.
Pharmacology|January 1, 1979
Effect of coadministration of procainamide and isoniazid on each other's acetylation pathwayD W Schneck, J S Sprouse, R A Shiroff, et al.
Clinical Pharmacology and Therapeutics|July 1, 1984
Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenonJ R Luderer, G G Nicholas, M M Neumyer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|April 1, 1984
Mechanism by which hydralazine increases propranolol bioavailabilityD W Schneck, J E Vary
Clinical Pharmacology and Therapeutics|June 1, 1980
Effect of dose and uremia on plasma and urine profiles of propranolol metabolitesD W Schneck, J F Pritchard, T P Gibson, et al.
Clinical Pharmacology and Therapeutics|May 1, 1990
Novel multivalent effects of pyrazinoylguanidine in patients with azotemiaK H Beyer, R T Gelarden, J E Vary, et al.
Clinical Pharmacology and Therapeutics|December 1, 1978
Plasma levels of free and acid-labile hydralazine: effects of multiple dosing and of procainamideD W Schneck, J S Sprouse, K Miller, et al.
Journal of Clinical Pharmacology|June 1, 1993
Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiencyK H Beyer, T D Ward, J E Vary, et al.
Pharmacology|January 1, 1979
Effect of coadministration of procainamide and isoniazid on each other's acetylation pathwayD W Schneck, J S Sprouse, R A Shiroff, et al.
Clinical Pharmacology and Therapeutics|July 1, 1984
Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenonJ R Luderer, G G Nicholas, M M Neumyer, et al.
Pageof 1